Therapeutic treatment with a novel hypoxia-inducible factor hydroxylase inhibitor (TRC160334) ameliorates murine colitis.

ABSTRACT:

Background and aim

Mucosal healing in inflammatory bowel disease (IBD) can be achieved by improvement of intestinal barrier protection. Activation of hypoxia-inducible factor (HIF) has been identified as a critical factor for barrier protection during mucosal insult and is linked with improvement in symptoms of colitis. Although prophylactic efficacy of HIF hydroxylase inhibitors in murine colitis have been established, its therapeutic efficacy in clinically relevant therapeutic settings have not been established. In the present study we aim to establish therapeutic efficacy of TRC160334, a novel HIF hydroxylase inhibitor, in animal models of colitis.

Methods

The efficacy of TRC160334 was evaluated in two different mouse models of colitis by oral route. A prophylactic effica

SUBMITTER: Gupta R 

PROVIDER: S-EPMC3908906 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature